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Abstract
Objective: To review the pseudotumors and tumors of the temporomandibular joint (TMJ) published in journals 
included in Journal Citation Reports (JCR), and to evaluate whether there are clinical and radiological signs capa-
ble of differentiating between pseudotumors and tumors and between malignant and benign tumors.
Material and Methods: A systematic Medline search was made of clinical cases of tumors and pseudotumors of the 
TMJ covering a 20-year period and published in journals included in JCR. Only cases with histological confirmation 
were included. A description is provided of the general characteristics of TMJ tumors, with comparison of the clini-
cal, diagnostic, therapeutic and evolutive variables referred to pseudotumors, benign tumors and malignant tumors.
Results: We identified 285 TMJ tumors published in 181 articles of 15 journals. The most frequent lesions were 
pseudotumors (synovial chondromatosis, pigmented villonodular synovitis, eosinophilic granuloma and osteo-
chondroma). The mean age was 42 years and one month ± 16 years and two months. Tumors were more common in 
females. The mean time from symptoms onset to consultation was 30 months and 8 days ± 41 months and 9 days, 
and almost 19.6% of the cases initially had been diagnosed and treated as TMJ dysfunction. The most frequent 
clinical manifestations were pain, swelling and the limitation of joint movements. The most common radiological 
findings in the case of benign and malignant lesions were radiopacities and radiotransparencies, respectively. No 
panoramic X-ray alterations were observed in 14.6% of the benign tumors and in 7.7% of the malignant lesions. 
Surgery was the usual form of treatment. Sequelae were recorded in 18.2% of the cases, with tumor relapse in 
9.1%. The four-year survival rate in the case of malignant tumors was 72.2%.
Key words: Tumor, temporomandibular joint, metaplasia, pseudotumor, condyle.
Poveda-Roda R, Bagán JV, Sanchis JM, Margaix M. Pseudotumors and 
tumors of the temporomandibular joint. A review. Med Oral Patol Oral 
Cir Bucal. 2013 May 1;18 (3):e392-402.   
 http://www.medicinaoral.com/medoralfree01/v18i3/medoralv18i3p392.pdf
Article Number: 18799         http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.18799
http://dx.doi.org/doi:10.4317/medoral.18799
Med Oral Patol Oral Cir Bucal. 2013 May 1;18 (3):e392-402.                                                                                                                                                                                                 TMJ tumors
e393
Introduction
Temporomandibular joint (TMJ) disorders, also generi-
cally referred to as TMJ dysfunction or derangement 
(TMJD), are relatively common (1) and constitute the 
leading cause of orofacial pain of non-dental origin (2). 
Most of these disorders are benign and tend to resolve 
spontaneously (3). TMJ pseudotumors and tumors are in-
frequent (4), and clinically manifest in a way very similar 
to TMJD (5). Certain clinical manifestations can help us 
distinguish between TMJD and tumor disease: numb-
ness of the territories innervated by the trigeminal nerve 
branches, hearing loss, constant pain not influenced by 
mandibular movements, increased severity of symptoms, 
a lack of response to treatment, alterations in dental occlu-
sion, the presence of swelling (including adenopathies), 
unexplained weight loss, ear suppuration or swallowing 
difficulties (6). However, these manifestations are not 
present in all cases, and many patients with TMJ tumors 
are initially diagnosed and treated as cases of TMJD (7). 
The resulting delay in establishing the correct diagnosis 
causes increased suffering, a greater risk of treatment 
complications and, in the case of malignant tumors, an 
increased threat to patient survival. In this context it is 
necessary to identify the symptoms, signs and radiologi-
cal alterations advising the inclusion of TMJ tumors in 
the differential diagnosis (8).
There are a number of TMJ lesions that are characterized 
by tissue growth, but which have not been clearly estab-
lished as true tumors (9-11) (osteochondroma, pigmented 
villonodular synovitis, eosinophilic granuloma). There 
is widespread agreement that synovial chondromatosis 
corresponds to metaplastic transformation of synovial 
tissue into chondroid tissue. Independently of the debate 
as to whether these are genuine tumors or not, we have 
included them as pseudotumors in this review.
The present study reviews the TMJ pseudotumors and tu-
mors published over the last 20 years in journals included 
in Journal Citation Reports (JCR) under the category 
Dentistry, Oral Surgery and Medicine, and an evaluation 
is made of whether there are clinical and radiological signs 
capable of differentiating between pseudotumors and tu-
mors and between malignant and benign tumors of the 
TMJ, with tabulation of the clinical, therapeutic and prog-
nostic findings of the most common TMJ neoplasms.
Material and Methods
A list was obtained of the journals included in JCR un-
der the category Dentistry, Oral Surgery and Medicine 
up until December 2009 (56 journals).
A Medline search was made using the following terms 
and boolean operators: temporomandibular AND tumor, 
temporomandibular and pseudotumor, condyle AND tu-
mor, condyle AND pseudotumor, synovial chondromato-
sis AND temporomandibular, osteocartilaginous exos-
tosis AND temporomandibular, eosinophilic granuloma 
AND temporomandibular, pigmented synovitis AND 
temporomandibular. The search was limited to a time 
period of 20 years (from 1 January 1990 to 31 December 
2009), and included only case reports and case series.
From the list of articles thus obtained, a manual selection 
was made of those papers containing descriptions of clini-
cal cases of TMJ pseudotumors and tumors published in 
journals included in the JCR under the category Dentistry, 
Oral Surgery and Medicine. All included cases were re-
quired to have histological confirmation of the diagnosis. 
Three articles were excluded due to a lack of histologi-
cal confirmation. The only exception to this requirement 
was the presence of metastases, in which a Department of 
Oncology confirmed the TMJ lesion as representing the 
metastatic expression of malignant disease.
The disease processes included in the study under the 
category pseudotumors were osteochondroma, synovial 
chondromatosis, pigmented villonodular synovitis and 
eosinophilic granuloma. In the present study the term 
“benign lesions” is used in joint reference to pseudotu-
mors and benign tumors.
Pseudotumors and tumors of the mandibular coronoid 
process were not included in the study.
A descriptive statistical study was made, expressing 
qualitative variables as absolute and relative frequen-
cies, and quantitative data as the mean and standard de-
viation. The comparative analysis was based on the chi-
squared test and analysis of variance (ANOVA). Sur-
vival analysis in turn was based on the Kaplan-Meier 
test and the Mantel-Cox log-rank test.
Dichotomic clinical manifestations and the imaging 
study data were subjected to diagnostic validity testing 
(sensitivity (Se), specificity (Sp), positive predictive val-
ue (PPV) and negative predictive value (NPV)), though 
only those yielding values of over 90% have been in-
cluded in the text.
In table 1 Chi-square test is used to analyze differences in 
clinical variables between tumors and pseudotumors and 
between benign and malignant tumors. For tables 2,3,4 
three quality levels have been established according to 
the number of cases included in the publication and the 
number of cases offering information referred to a concrete 
study variable. The data of adequate quality (over 20 cases 
and information referred to a concrete variable available 
in over 66% of the cases) appear in the tables over a dark 
gray background. Medium quality data (over 20 cases and 
information available in 33-66% of the cases, or between 
10-20 cases and information available in over 66% of the 
cases) in turn appear over a light gray background, while 
limited quality data (fewer than 10 cases and information 
available in under 33% of the cases, or between 10-20 cas-
es and information available in under 66% of the cases) 
appear over a white background. This simply constitutes 
an ad hoc system for classifying the quality of the clinical 
information contained in the articles.
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Results and Discussion
-Bibliometric data
Temporomandibular joint tumors were seen to be pub-
lished in 15 of the 56 journals included in the review 
(26.8%). Most of them were found in the Journal of 
Oral and Maxillofacial Surgery (30.2%), Oral Surgery 
Oral Medicine Oral Pathology Oral Radiology and En-
dodontics (18.6%), the International Journal of Oral 
and Maxillofacial Surgery (12.6%), Dentomaxillofacial 
Radiology (11.9%), and the British Journal of Oral and 
Maxillofacial Surgery (8.4%).
We identified 285 tumors and pseudotumors of the TMJ 
published in 181 articles. Most corresponded to isolated 
cases (156 lesions, 54.7%), while the rest (129 lesions, 
45.3%) were case series involving 2-14 cases each. The 
number of publications per year ranged from three (in 
1995) to 18 (in 2007).
Table 1 contains frequency of clinical manifestations, 
comparison between tumors and pseudotumors and 
comparison between benign tumors and malignancies. 
Tables 2,3,4 contain epidemiological, clinical, diagnos-
tic prognostic and therapeutic data about the most com-
mon tumors of the TMJ.
-Clinical data
Most of the 285 identified lesions were benign (81.8%). 
However, on excluding the pseudotumors (synovial 
chondromatosis, pigmented villonodular synovitis, 
eosinophilic granuloma and osteochondroma), the situ-
ation changed drastically; in effect, of the 81 tumors 
which could be regarded as true tumors, almost two-
thirds (64.2%) were seen to be malignant.
The lesions were usually diagnosed in young individu-
als (mean age 42 years and 2 months ± 16 years and 2 
months), though with a broad age range (4-81 years). 
These figures remained similar on excluding the pseu-
dotumors from the analysis and limiting the study to the 
true tumors (mean age 42 years and 6 months, ± 20 years 
and 3 months) (range 4-78 years). Different results were 
obtained on comparing the age of patients with benign 
lesions versus those with malignant tumors. In effect, the 
latter were significantly older at the time of diagnosis than 
the patients with benign lesions (48 years and 9 months ± 
19 years and 1 month versus 40 years and 6 months ± 15 
years and 1 month; t=3.65, p<0.002). The recorded mean 
age is consistent with the 51 years reported by Bavitz et 
al. (12) at the time of diagnosis of malignant TMJ tumors. 
On excluding pseudotumors from the analysis, the dif-
ference in age between the benign and malignant tumors 
was found to increase, since the mean age of the patients 
with true benign tumors was 31 years and 4 months ± 17 
years and 6 months (t=4.2, p<0.000). It is advisable to in-
clude malignant TMJ tumors in the differential diagnosis 
in the case of elderly patients showing a sudden onset of 
symptoms (13).T
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In the same way as TMJ derangement or dysfunction 
(TMJD), temporomandibular joint tumors are more fre-
quent in females than in males (14). However, as the se-
riousness of the process increases, the gender difference 
decreases. Two-thirds of the pseudotumors and tumors 
were identified in women (66.3%) (female-male ratio 
1.97:1). On excluding the pseudotumors and limiting the 
analysis to the true tumors, this female predominance 
was seen to decrease to 55.4%. A total of 51.7% of the 
true benign tumors and 57.4% of the malignant tumors 
were diagnosed in women. Bavitz et al. reported a similar 
frequency of malignant tumors in men and women (12).
Figure 1 shows the observed diseases and their frequen-
cy. The pseudotumors were clearly the most numerous, 
representing over two-thirds of the lesions (71.6%). 
Synovial chondromatosis accounted for almost one-half 
of the cases (44.2%) and 61.8% of the pseudotumors. 
Benign mesenchymal tumors were the most frequent 
true tumors, followed by sarcomas and metastases. Our 
findings differ from those reported by Allias et al., who 
found the most frequent malignant TMJ tumors to be 
metastases (15).
The mean time from symptoms onset to first consul-
tation was approximately 2.5 years (30 months ± 41 
months and 10 days), though this interval could not be 
established in 35.4% of the cases. A statistically signifi-
cant difference was observed in the mean time from 
symptoms onset to first consultation between benign 
lesions (3 years ± 3 years and 9 months) and malignan-
cies (9 months and 14 days ± 13 months and 23 days) 
(t=6.35; p=0.000). On analyzing only the true benign 
tumors, the mean time decreased slightly to 25 months 
and 22 days - the difference with respect to the malig-
nant tumors remaining statistically significant (t=3.07; 
p=0.005).
The clinical manifestations of TMJ pseudotumors and 
tumors are very similar to those of TMJD, thereby fre-
quently giving rise to errors in diagnosis and to inad-
equate treatment. In effect, one out of every 5 cases 
(19.6%) in our study initially had been diagnosed and 
treated as TMJD. However, the true percentage is very 
likely quite higher, since this information was not avail-
able in two-thirds of the cases (66.7%). The conclusions 
that can be drawn on analyzing the cases where the di-
Fig. 1. Distribution of temporomandibular joint tumors and pseudotumors.
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agnostic and treatment information was available are of 
clinical relevance, since among the pseudotumors and 
benign tumors it was available in 29.2% of the cases, 
and of these, two-thirds (63.2%) initially had been di-
agnosed and treated as TMJD. In turn, in the malignant 
tumors the information was available in one-half of the 
cases, and in 48.1% the patients initially had been diag-
nosed and treated as TMJD.
Table 1 shows the dichotomic clinical variables corre-
sponding to the global tumors and to the true tumors 
and pseudotumors considered separately, with an analy-
sis of the differences between them. The benign lesions 
and malignant tumors are likewise considered separate-
ly, with an analysis of the differences between them. 
Swelling presented a negative predictive value of over 
90% for malignant tumors (91.2%).
The analyzed qualitative clinical variables with more 
than two categories and quantitative clinical variables 
were lesion consistency, joint sounds, clinical size and 
occlusal alterations. The clinical consistency of the le-
sion was only documented in 40 cases (13.9%); the great 
majority were found to be hard in response to palpation 
(82.5%) with no differences between pseudotumors and 
tumors (χ2=2.40; p=0.12) or between benign and malig-
nant tumors (χ2=1.28; p=0.26).
Information on the presence or absence of joint sounds 
was available in 54.7% of the patients. Clicks were 
the most frequent sounds (40.4%), followed by crepi-
tus (21.8%). One-third of the tumors produced no joint 
sounds (33.3%). Both clicks and crepitus were more 
common among the pseudotumors than in the tumors 
(χ2=16.1; p=0.003). No significant differences were re-
corded between malignant and benign tumors in terms 
of joint sounds (χ2=1.36; p=0.72), and in both cases 
clicks were the most frequent sound.
Occlusion alterations, one of the signs most suggestive of 
joint tumors together with the presence of swelling, were 
reported in 20.5% of the patients – this proportion be-
ing slightly greater than the 10% reported by Bavitz et al. 
for malignant tumors (12). In one-third of the cases there 
were no occlusion disorders, and in almost one-half of 
the cases studied (44%) no mention was made of whether 
such alterations were recorded or not. The most common 
occlusal disorders were ipsilateral posterior open bite, 
contralateral cross-bite and anterior cross-bite. Contral-
ateral open bite, ipsilateral cross-bite or anterior open bite 
was reported in less than 2% of the cases. Ipsilateral open 
bite - one of the most suggestive clinical signs - was only 
documented in one-third of the tumors (34.0%) in which 
the presence of occlusal disorders was registered. Simi-
lar findings apply to contralateral cross-bite, which was 
only reported in 14 of the 285 tumors (4.9%). There were 
no significant differences in occlusion disorders between 
pseudotumors and tumors (χ2=0.80; p=0.67) or between 
benign and malignant tumors (χ2=3,9;p=0.14).
-Imaging techniques
The panoramic X-ray (P-Rx) study revealed the presence 
of a radiotransparency in approximately one out of every 
5 patients (19.1%), a radiopacity in 13.9%, and mixed im-
ages in 6.3%. Two findings appear particularly relevant: 
in almost one-half of the cases (46.5%) no mention was 
made of whether there were P-Rx alterations or not, and 
in 40 cases (14.0%) such alterations were reported to be 
absent – this being explained by the fact that a calcium 
loss of 50% or more is required in order for the lesion 
to be radiographically visible (12)-. Radiotransparencies 
were significantly more frequent in the tumors (77.8%) 
than in the pseudotumors (22.0%) (χ2=40.9; p=0.000). 
In contrast, radiopacities were significantly more com-
mon in the pseudotumors (61.0%) than among the tumors 
(7.4%). The most common imaging finding in the benign 
lesions was radiopacity – the latter not being seen in any 
of the malignant tumors. Among the malignancies, radi-
otransparencies were the most frequent image (53.7%); 
however, it would not be correct to conclude that radi-
otransparencies are pathognomonic or characteristic of 
malignancy, since they were also reported in 11.1% of 
the benign tumors. Nevertheless, perhaps the most rel-
evant observation was the fact that almost one of every 
10 malignant tumors (9.3%) showed no P-Rx alterations. 
Radiotransparency presented a negative predictive value 
of 90.8% for malignant tumors.
On limiting the analysis to the true benign tumors, the 
radiological pattern was seen to change, with a pre-
dominance of radiotransparencies (44.8%). Neverthe-
less, radiotransparent images remained significantly 
more frequent among the malignant tumors (χ2=9.05; 
p=0.01). As regards lesion delimitation, P-Rx estab-
lished clear differences between benign and malignant 
tumors, though unfortunately this information was only 
available in 103 of the 285 tumors (36.5%). The great 
majority of the benign tumors (80.3%) showed a well 
delimited contour, while practically the same propor-
tion of malignancies (79.3%) exhibited a poorly delim-
ited contour. The difference was statistically significant 
(χ2=31.37; p=0.000). A poorly defined contour in the 
P-Rx study presented a negative predictive value of 
90.0% for malignant tumors.
Computed tomography (CT) was available in 159 cases 
(55.8%). The frequency of radiopaque images in the CT 
study was greater in the case of benign lesions than in 
the malignant tumors (19.2% versus 3.7%), while mixed 
and soft tissue patterns were more frequent among the 
latter (29.6% and 14.8% versus 11.1% and 3.8%, respec-
tively) (χ2=36.8; p=0.000). The data referred to lesion 
contour were practically analogous to those recorded in 
the P-Rx study – 81.2% of the benign lesions showing 
a well delimited contour, while 76.9% of the malignant 
tumors presented a poorly delimited contour (χ2=41.76; 
p=0.000). Of note is the observation that approximately 
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20% of the patients with malignant tumors presented 
a lesion with well delimited contours in both the P-Rx 
study and the CT scan. The invasion of adjacent soft tis-
sues as evidenced by CT was significantly more frequent 
in the malignant tumors (85.7%) than in the benign le-
sions (29.9%)(χ2=28.7; p=0.000). The negative predic-
tive value of the invasion of soft tissues was 90.3%.
-Treatment and outcome
Surgery was the treatment prescribed in most of the tu-
mors. A preauricular approach was used in almost one-
half of the patients (48.0%), though the true percentage 
is probably considerably greater, since information re-
ferred to the surgical approach was not available in over 
a third of the cases (36.5%). Arthroscopic treatment was 
used in 7.3% of the cases, and practically all of these 
corresponded to synovial chondromatosis (95%). In 58 
benign lesions (24.9%) no mention was made of the 
type of treatment provided. In the cases where such in-
formation was available (176 patients, 75.5%), the most 
frequent treatment was found to be total or partial syn-
ovectomy (34.7%). This is because synovectomy is the 
technique of choice in synovial chondromatosis, which 
accounted for 44.2% of all the tumors. The rest of the 
treatments in decreasing order of frequency were sim-
ple tumor resection (23.3%), resection with safety mar-
gins (9.8%), and simple foreign body removal (7.4%), 
which is also one of the options in synovial chondroma-
tosis. The most common surgical procedure in the case 
of malignant disease was tumor resection with margins 
(46.2%), followed by simple tumor resection (20.5%). 
In comparison, in the benign tumors, the most frequent 
treatment was simple resection (53.6%), followed by 
condylectomy (17.9%). In 31 tumors, use was made of 
radiotherapy or chemotherapy, or a combination of both 
(13, 6 and 12 patients, respectively). All but one of these 
cases (osteoid osteoma) were malignant.
The mean duration of patient follow-up was 30.5±30.1 
months, with a median of 22.5 months. In 84 cases (29.5%) 
information referred to the duration of follow-up was not 
available. A little over one-half of the patients (54.2%) 
suffered no sequelae following treatment, while 18.4% 
experienced some problems. In the rest of the cases no 
mention was made of whether there were sequelae or not. 
Among the 54 cases in which treatment complications 
were reported, the most common problems were man-
dibular deviation (27.8%), limited range of movement 
(16.7%), facial palsy (7.4%) and crepitus and pain (5.5% 
in each case). Fifteen patients (27.8%) died as a result of 
the neoplasm (all corresponding to malignant tumors).
Kaplan-Meier survival analysis of the 39 malignant tu-
mors followed-up on for a period of 3-96 months yield-
ed an estimated mean survival of approximately 5 years 
(57.9 months; standard error (SE) 7.6, 95% confidence 
interval (95%CI) 43.0-72.7 months). On differentiating 
between metastasis and the rest of malignant tumors, 
we found metastatic disease to present a survival of 
about one year (11.4 months; 95%CI 8.6-14.1 months), 
while the rest of the malignant tumors showed a mean 
survival of 6 years (72.9 months; SE 7.8, 95%CI 57.6-
88.3). Comparison based on the Mantel-Cox log-rank 
test showed the difference to be statistically signifi-
cant (χ2=24.4; p=0.000) (Fig. 2). In contrast, sarcomas 
(the most frequent malignant tumors of the TMJ in 
our study) showed longer survival than the non-sar-
comatous malignancies (plasmacytomas, lymphomas, 
metastases, etc.), with a mean of 69.7 months (SE 9.5, 
95%CI 51.1-88.3 months) versus 40.2±9.7 months in 
the case of the rest of malignant tumors. The log-rank 
test showed the difference to be statistically significant 
(χ2=46; p=0.03) (Fig. 3). Survival after 5 years among 
the TMJ sarcoma patients (65%) was similar to that re-
ported by Yamaguchi et al. for oral and maxillofacial 
sarcomas (61%) (16).
Tumor relapse was documented in 26 cases (9.1%), of 
which 10 corresponded to benign lesions (4.3%) and 16 
to malignant tumors (30.8%). On comparing propor-
tions, and as expected, relapse was significantly more 
common in the case of malignant disease than in patients 
with benign tumors (χ2=36.5; p=0.000). No significant 
differences were observed in terms of the frequency of 
relapse between true benign tumors and pseudotumors 
(χ2=0.24; p=0.63). Of the mentioned 10 benign tumor re-
lapses, three were osteochondromas, three corresponded 
to synovial chondromatosis, two were eosinophilic gran-
ulomas, one was diagnosed as osteoblastoma and another 
corresponded to osteoma. Regarding the malignant tu-
mors, of the 17 relapses, 10 corresponded to metastasis, 
while four were sarcomas (angiosarcoma, synovial sar-
coma and leiomyosarcoma), two plasmacytomas and one 
Hodgkin lymphoma. Curiously, the chondrosarcomas 
and osteosarcomas - representing 26% of the malignant 
tumors and 50% of the sarcomas - showed no relapses in 
our study. In contrast, Yamaguchi et al. reported relapse 
or metastasis in 5 out of 9 orofacial osteosarcomas (16), 
while Oliveira et al. described recurrences in 9 out of 20 
chondrosarcomas of the TMJ (17).
In conclusion, tumors of the temporomandibular joint 
are characteristically found in young adults, and be-
cause of the scant specificity of the symptoms, many 
of them are initially diagnosed and treated as tempo-
romandibular joint derangement. Pain, swelling and 
the limitation of joint movements are the most frequent 
clinical manifestations. Other more specific alterations 
such as facial asymmetry or occlusal disorders, are less 
common. Many tumors show no radiological alterations 
in the P-Rx study. Radiotransparency, and especially a 
poorly defined tumor contour, are suggestive of malig-
nancy. Treatment usually involves surgery, and relapse 
is observed in 10% of the cases – particularly among 
malignant tumors.
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Fig. 2. Comparison of survival in temporomandibular joint metastatic disease versus other malignancies of 
the temporomandibular joint.
Fig. 3. Comparison of survival in temporomandibular joint sarcomas versus other malignancies of the temporo-
mandibular joint.
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